BiotechTube
Asymmetrex

Asymmetrex

Pre-clinical
Boston, United StatesFounded 20131-10 employeesasymmetrex.co

Asymmetrex's mission is to solve the long-standing problem of counting tissue stem cells, a fundamental barrier in stem cell biology and medicine. The company's proprietary Kinetic Stem Cell Counting technology provides a functional assay to determine the number and concentration of therapeutic stem cells, which is critical for standardizing stem cell transplantation, manufacturing, and drug testing. By enabling precise stem cell dosage, Asymmetrex aims to improve the safety, efficacy, and commercialization of stem cell therapies and accelerate pharmaceutical development. The company operates as a private entity, leveraging its platform through research collaborations, service offerings, and technology licensing.

Market Cap
Private
Pipeline
—
Patents
—
Publications
—

Private Company

Total funding raised: $6.0M

AI Company Overview

Asymmetrex's mission is to solve the long-standing problem of counting tissue stem cells, a fundamental barrier in stem cell biology and medicine. The company's proprietary Kinetic Stem Cell Counting technology provides a functional assay to determine the number and concentration of therapeutic stem cells, which is critical for standardizing stem cell transplantation, manufacturing, and drug testing. By enabling precise stem cell dosage, Asymmetrex aims to improve the safety, efficacy, and commercialization of stem cell therapies and accelerate pharmaceutical development. The company operates as a private entity, leveraging its platform through research collaborations, service offerings, and technology licensing.

Regenerative MedicineCell TherapyOncologyHematology

Technology Platform

Kinetic Stem Cell (KSC) Counting technologies provide rapid, accurate counting and monitoring of tissue stem cells present in cell-heterogeneous tissue cell preparations through functional assessment of asymmetric self-renewal kinetics.

Funding History

6
Total raised:$6.0M
Grant$905KSep 17, 2024
Seed$2.5MJan 15, 2022
Grant$420KSep 19, 2020
Grant$1.8MAug 15, 2019

Opportunities

The growing stem cell therapy market creates increasing demand for standardization and quality control, where Asymmetrex's technology addresses a fundamental need.
Expansion into pharmaceutical safety testing represents a significant adjacent market opportunity.
The platform's applicability across multiple stem cell types and therapeutic areas provides diversified growth potential.

Risk Factors

Technology adoption risk as the market may be slow to transition from established stem cell counting methods.
As a small private company, limited resources may constrain commercialization speed.
Regulatory acceptance for clinical applications may require extensive validation studies.

Competitive Landscape

Faces competition from traditional flow cytometry methods and colony-forming assays, but offers superior functional assessment. Limited direct competitors in the specific niche of kinetic stem cell counting. Differentiation through patented technology that directly measures stem cell function rather than surrogate markers.